Steve Vintz
Analyst · Morgan Stanley. Please proceed with your question
Thanks Amit. As Amit mentioned earlier, we are delighted with the results for the fourth quarter highlighted by significant acceleration in CCB growth, a notable beat in earnings per share and attractive levels of unlevered free cash flow. I will provide more commentary on each of these points momentarily, but first please note that all financial results we discuss today are non-GAAP financial measures, with the exception of revenue. As Erin mentioned at the start of this call GAAP to non-GAAP reconciliations may be found in our earnings release issue earlier today, which is posted on our website. Now onto our results for the quarter. Revenue for the quarter was $149 million, which represents 26% year-over-year growth. Revenue in the quarter exceeded the midpoint of our guided range by $5 million. Visibility remains high as our percentage of recurring revenue was 95%, which is primarily a result of our annual prepaid subscription model. Revenue for the full year was $541.1 million, which represents 23% growth year-over-year. The outperformance in revenue is a result of accelerating growth in calculated current billings. CCB, defined as the change in current deferred revenue plus revenue recognized in the quarter, grew 29% year-over-year to $194 million. Q4 forecast a very successful year for us in which we saw CCB growth accelerate throughout the year from 20% in Q1 to 23% in Q2 to 25% in Q3 and now to 29% in Q4. We attribute this inflection in growth to our differentiated VM capabilities, expanding product portfolio and increased investment in sales capacity and go-to-market activities. During Q4, we saw strength across the board in both new and renewal business and in all geographies. It's important to note that we experience very good linearity entering December, and we're on our way to one of our best growth quarter of the year. However, after the discovery of Log4j in December, we saw a significant uptick in our expansion rates as customers increased coverage of both assets and applications. Our expansion rate also benefited from exceptional renewals, including winbacks and limited customer churn, all of which lifted our net dollar expansion rate. Likewise, we also saw outperformance in new logos, particularly in the mid-market through our inside sales efforts and from no touch Nessus sales channels given the relatively short sales cycles. New logo sales from large market customers with longer sales cycles also saw strong close rates for opportunities that were already advanced in the Q4 pipeline. New pipeline built in the quarter for the large market was also very healthy. Now in terms of metrics underpinning our strong financial performance, we added 562 new enterprise platform customers in the quarter, which is a record for us and up from the 460 we added in Q4 last year. We also had success with large deals as we added 100 net new six-figure customers in the quarter, which is up from 66 in the same period last year. Similar to new enterprise platform customers, the number of net new six-figure customers we added in Q4 is our largest ever in a single quarter and brings the total number of new enterprise platform customers spending over 100,000 per annum to almost 1,100. From a product mix perspective, our exposure solutions, which includes Tenable.io, Tenable.ep, and as modules active directory security and operational technology security continue to gain traction and solve outside's growth. We attribute this strong demand to our customers need to assess risk holistically across IP assets, identities and OT assets. While we saw strength in cloud use cases, it should be noted that Accurics contribution to CCB in the quarter was nominal since the acquisition closed in Q4 and Accurics infrastructure as code capabilities were not integrated into our go-to-market motion in the quarter. We've believe Accurics ability to assess and secure critical cloud infrastructure prior to deployment will significantly enhance our existing cloud capabilities and augment our strength in one-time environments. Accordingly, we plan to soon announce the availability of our more expansive cloud security offering and the integration of these capabilities with EP shortly, and given sales cycles we expect CCB to begin to benefit in the second half of the year. In summary, we are delighted with the trend in the top line this year. Now, I'll turn to expenses, which include incremental investments in growth and the operating expenses related to Accurics. I'll start with gross margin, which was 82% this quarter, down 70 basis points from last quarter. Gross margin from the full year was also 82%. Cost to sales increase sequentially due to higher public cloud and related costs associated with the increased customer usage of our products and cost related to scaling the Accurics' infrastructure and support of a more expansive cloud security offering. We are also investing in a broader set of advanced analytics across the attack surface to help customers better predict attack path and assess risk holistically. Looking ahead, we expect these investments to continue into 2022, which could modestly impact gross margin. Long-term, we still expect gross margins to be in the high 70% to low 80% range. Sales and marketing expense for the quarter was $69.5 million, which is up from $60.7 million last quarter. Sales and marketing expense reflects higher wages and benefits related to hiring more sales reps and other headcount, as well as accrued payroll taxes. Further, it reflects higher commissions and variable compensation attributed to our strong sales performance in the quarter, an increased investment in marketing for demand gen and brand building activities for our exposure solutions. Adding sales capacity and investing in our go-to-market efforts will continue to be an area of focus for us, given the acceleration in growth in 2021, our expanded product portfolio and the high level of sales productivity, as well as our ability to generate an attractive ROI on new dollars invested. Sales and marketing expense as a percentage of revenue was 47% in Q4 compared to 44% last quarter. For the full year, sales and marketing expense as a percent of revenue was 44% and is expected to remain at or near this percentage in 2022, which will give us ample investment dollars to keep pace with a strong demand. R&D expense for the quarter was $24.9 million, which was consistent with $25.1 million last quarter. Although, there was little change in R&D expense during the quarter, it should be noted that we added a sizeable team of engineers in cloud security attributed to Accurics and made other hires, which was more than offset by the amount of capitalized software development costs related to expanding our exposure platform and in R&D tax credit we received. R&D expense as a percentage of revenue was 17% in Q4 compared to 18% at last quarter. For the full year R&D expense as a percentage of revenue was 18% and is expected to increase modestly in 2022, given the increase investment in cloud security, attack path analysis attributed to the Cymptom acquisition and a broader set of predictive analytics and platform capabilities. G&A expense was $15.8 million compared to $15 million last quarter. As a percentage of revenue, G&A expense was 11% this quarter and last quarter, as well as for the full year. We continue to make investments in G&A to support growth and scale of our business. We expect G&A expense as a percentage of revenue to remain flat in 2022. Income from operations was $11.9 million compared to $13.7 million last quarter, which reflects the items I just highlighted. For the full year, non-GAAP income from operations was $51 million compared to $25.8 million in 2020, which was a $25 million improvement despite the additional operating expenses attributed to the Alsid and Accurics acquisitions. Operating margin was 8% for Q4 compared to 10% last quarter. Operating margin was 9% for the full year compared to 6% for the full year 2020. EPS in the fourth quarter was $0.05, which was 0.02 better than the high end of our guided range. For the full year, we generated $0.34 of earnings per share versus $0.19 last year. Now, let's turn to the balance sheet. We finished the quarter with $512 million in cash and short-term investments. Given our strong Q4 results, we saw a notable sequential increase in both accounts receivable and total deferred revenue. At year-end, accounts receivable was $137 million and total deferred revenue was $531 million, including $407 million of current deferred revenue, which gives us a lot of visibility headed into 2022. Now I would like to discuss cash flow. We used $160 million of cash to acquire Accurics and paid $3.2 million of interest on our credit facility in October. In Q4, we generated $22.4 million of unleveraged free cash flow and for the year we generated $95.2 million, which is a $50.9 million increase over 2020 levels. With 95% recurring revenue, high gross margins and high renewal rates, we feel confident that we can continue to generate attractive levels of cash while continuing to invest in the business. Striking the right between growth and profitability has always been an area of focus for us. A good indication of this is our achievement of rule of 40 for the fourth quarter and full year. Achieving this was years in the making and a long term goal since our IPO in 2018. So, we're very pleased to have achieved this important milestone. As a reminder, we define rule of 40 as revenue growth plus unlevered free cash flow margin. With the results of the quarter behind us, I'd like to our outlook for the first quarter and full year 2022. For the first quarter, we currently expect revenue to be in the range of $152 million to $154 million; non-GAAP income from operations to be in the range of $10 million to $11 million; non-GAAP net income to be in the range of $5.2 million to $6.2 million, assuming interest expense of $3.5 million and a provision for income tax of $1.3 million; non-GAAP diluted earnings per share to be in the range of $0.04 to $0.05, assuming $117.5 million fully diluted weighted average shares outstanding. And for the full year, we currently expect calculated current billings to be in the range of $750 million to $760 million; revenue to be in the range of $662 million to $670 million; non-GAAP income from operations to be in the range of $40 million to $45 million; non-GAAP net income to be in the range of $18.2 million to $23.2 million, assuming interest expense of $14 million and a provision for income taxes of $8 million; non-GAAP diluted earnings per share to be in the range of $0.15 to $0.19, assuming $119.5 million fully diluted weighted average shares outstanding. Our strong performance in Q4 and the full year 2021 give us a lot of confidence in the business and our outlook for 2022. In that regard, there are a few comments I want to make that will provide important context to our guidance today. Our CCB guidance for the full year reflects 22% to 23% growth, which includes some continued tailwinds from Log4j in Q1 with more modest contributions expected throughout the remainder of the year. Overall, we're very pleased to be providing CCB and revenue guidance today that is notably above the 20% bar we discussed during our Investor Day in December. In terms of profitability, we exit the year with an 8% operating margin in Q4 and are guiding to 6% to 7% from the full year 2022, which includes $4 million to $5 million per quarter of operating expenses related to Accurics and to a lesser degree Cymptom. The incremental investments in R&D attributed to recent acquisitions expand our product suites strategically important markets and strengthen our ability to deliver our cyber exposure vision. In terms of the quarterly flow of these investments, we expect to follow our historical seasonal patterns with higher rating in the first half of the year, resulting in higher operating margins the second half of the year. As discussed earlier, we achieved rule of 40 in Q4 and the full year 2021. So, we believe making investments in the face of strong demand will position us well for continue growth and success. Long-term, we are confident in our ability continue to balance growth with profitability and become a rule of 50 company. In summary, we're delighted with the results of the quarter and feel really good about the outlook we are providing today. I'll now turn the call back to Amit for some closing comments.